None listed
Conditions
Interventions
Intervention 1: Intervention group: Prescription of Azithromycin 500 mg capsule/200mg/5ml suspension manufactured by Dorsa Darou company from Iran in the first week. Intervention 2: Control group: Pre
Sponsors
Hezareh Sevom Futuristic Pharmacist
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 18 to 45 years old Sex: Males and/or non-pregnant, non-lactating females BMI: 18.5 to 24.9 weight in kg/(height in meter) Able to communicate effectively with study personnel and willingness to follow the protocol requirements as evidenced by written informed consent, A physical examination with no clinically significant finding and laboratory normal tests, Do not take any chronic or acute medication for at least 1 week before the start of the study No history of diseases affecting the pharmacokinetic processes of the drug
Exclusion criteria
Exclusion criteria: History of allergic responses to Azithromycin or other related drugs, or any of its formulation ingredients Have significant diseases (which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system) or clinically significant abnormal findings during screening Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period History or evidence of drug dependence or of alcoholism or of moderate alcohol use History of difficulty with donating blood or difficulty in accessibility of veins Volunteers who have received a known investigational drug within five elimination half life of the administered drug prior to the initial dose of study drug or who have participated in a clinical drug study or bioequivalence study within 90 days prior to the initial dose of study drug, whichever is greater found positive in urine test for drugs of abuse done before check-in of period History of difficulty in swallowing, or of any gastrointestinal disease which could affect drug absorption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration. Timepoint: 0,0.5, 1, 1.5, 2, 2.5, 3,3.5,4,5,6,8,12,24,48,72 hour. Method of measurement: LC MS MS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaranak Salmannejad
Alborze University of Medical Sciences, School of Pharmacy
Outcome results
None listed